XYZAL ALLERGY 24HR's oppositions filed in EPO
XYZAL ALLERGY 24HR Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8633194 | CHATTEM SANOFI | Pharmaceutical composition of piperazine derivatives |
Oct, 2027
(4 years from now) | |
Xyzal Allergy 24Hr is owned by Chattem Sanofi.
Xyzal Allergy 24Hr contains Levocetirizine Dihydrochloride.
Xyzal Allergy 24Hr has a total of 1 drug patent out of which 0 drug patents have expired.
Xyzal Allergy 24Hr was authorised for market use on 31 January, 2017.
Xyzal Allergy 24Hr is available in solution;oral dosage forms.
The generics of Xyzal Allergy 24Hr are possible to be released after 16 October, 2027.
Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2017
Treatment: NA
Dosage: SOLUTION;ORAL
How can I launch a generic of XYZAL ALLERGY 24HR before it's drug patent expiration?
More Information on Dosage
XYZAL ALLERGY 24HR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic